Chai Discovery partners with Roche: Chai's AI models enter drug discovery programs across Roche's therapeutic areas
Synopsis
Chai Discovery announced a collaboration with Roche to use Chai's AI models and platform in a number of drug discovery programs across Roche's therapeutic areas. Chai builds computer-aided design tools for protein-based therapeutics, and its latest model, Chai-3, is described by the company as achieving high target success rates and binding affinities, including against challenging targets. The deal is the latest in a series of 2026 collaborations Chai has announced with leading pharmaceutical companies; the announcement gives no program counts, specific targets or timelines.
Interpretation
Chai Discovery and Roche have formed a collaboration in which Roche will use Chai's AI models and platform in several drug discovery programs across its therapeutic areas. In the words of Chai CEO Joshua Meier, the collaboration expands the range of therapeutic programs that can benefit from AI-driven molecular design. The collaboration comes from Chai Discovery's announcement, which carries statements from Meier and from Boris L. Zaïtra, Head of Corporate Business Development at Roche, who said Chai's platform aligns well with Roche's research strategy.
The collaboration rests on Chai's AI models and platform for protein-based therapeutics, with its latest model, Chai-3, described by the company as achieving high target success rates and binding affinities. Chai positions its models as reasoning about biological structure and function and generating new molecular designs from scratch, so pharma teams can pursue targets that traditional discovery methods have struggled to reach, rather than finding medicines by trial and error. The announcement describes Chai-3 as achieving high target success rates and binding affinities, including to challenging targets, but gives no specific figures, target names or comparison baseline.
Perspective
What the announcement confirms is that Roche will use Chai's AI models and platform in several drug discovery programs across multiple therapeutic areas; readers should treat it as a collaboration arrangement, not as proof of efficacy or clinical progress. The announcement does not state program counts, specific targets, timelines or financial terms.
The announcement describes Chai-3 only qualitatively, saying it achieves high target success rates and binding affinities including to challenging targets, without specific figures or a comparison baseline; the collaboration itself discloses neither program counts nor stage.